7 results about "Interleukin-6 receptor" patented technology

The invention discloses an antibody or an antigen binding fragment capable of specifically recognizing and / or binding an anti-interleukin 6 receptor. Belongs to the field of antibody engineering. The antibody or the antigen binding fragment provided by the invention has higher biological activity, FcRn affinity and stronger antibody stability, and has a good clinical application prospect.

Provided herein are an antibody or antigen binding fragment that specifically recognizes and / or binds to an anti-interleukin 6 receptor. The antibodies or antigen binding fragments provided by the present disclosure have biological activity, FcRn affinity and antibody stability, and have prospects for clinical application.

Provided is a pharmaceutical formulation with reduced particle formation, comprising an anti-coagulation factor IXa / X antibody (bispecific monoclonal antibody) that substitutes for coagulation factor VIII, or an anti-IL-6 receptor antibody that inhibits binding to the interleukin 6 receptor. Provided is a pharmaceutical formulation comprising an aqueous solution comprising a polyoxyethylene polyoxypropylene glycol (poloxamer),wherein the poloxamer is represented by formula I:HO(C2H4O)a(C3H6O)b(C2H4O)cH  (I)wherein a and c are independently an integer selected from 75 to 85;b is an integer selected from 22 to 33; anda, b and c are average values over the entire poloxamer, and,the poloxamer comprises poloxamer molecules comprising 34 or more (C3H6O) in the molecule at a ratio of 3% (w / w) or more of the total poloxamer.

The present invention relates to therapeutic and / or prophylactic agents for ocular inflammatory disease, which comprise an interleukin 6 (IL-6) receptor inhibitor as an active ingredient.

Provided is an antibody-drug conjugate having a structure represented by formula (I): Ab-(L-D)n (I), wherein Ab is an anti-interleukin 6 receptor antibody or an antigen-binding fragment thereof, D is a drug, L represents a linking group for linking Ab and D, and n is 1-10. The antibody or the antigen-binding fragment thereof comprises at least one light chain and at least one heavy chain. In addition, provided is use of the antibody-drug conjugate. The antibody-drug conjugate can significantly reduce the administration dosage, improve the tolerance of patients, and reduce adverse reactions.

Provided is a pharmaceutical formulation with reduced particle formation, comprising an anti-coagulation factor IXa / X antibody (bispecific monoclonal antibody) that substitutes for coagulation factor VIII, or an anti-IL-6 receptor antibody that inhibits binding to the interleukin 6 receptor. Provided is a pharmaceutical formulation comprising an aqueous solution comprising a polyoxyethylene polyoxypropylene glycol (poloxamer),wherein the poloxamer is represented by formula I:HO(C2H4O)a(C3H6O)b(C2H4O)cH  (I)wherein a and c are independently an integer selected from 75 to 85;b is an integer selected from 22 to 33; anda, b and c are average values over the entire poloxamer, and,the poloxamer comprises poloxamer molecules comprising 34 or more (C3H6O) in the molecule at a ratio of 3% (w / w) or more of the total poloxamer.

Provided is a pharmaceutical formulation with reduced particle formation, comprising an anti-coagulation factor IXa / X antibody (bispecific monoclonal antibody) that substitutes for coagulation factor VIII, or an anti-IL-6 receptor antibody that inhibits binding to the interleukin 6 receptor. Provided is a pharmaceutical formulation comprising an aqueous solution comprising a polyoxyethylene polyoxypropylene glycol (poloxamer),wherein the poloxamer is represented by formula I:wherein a and c are independently an integer selected from 75 to 85;b is an integer selected from 22 to 33; anda, b and c are average values over the entire poloxamer,and,the poloxamer comprises poloxamer molecules comprising 34 or more (C3H6O) in the molecule at a ratio of 3% (w / w) or more of the total poloxamer.